Pegfilgrastim enhances the antitumor effect of therapeutic monoclonal antibodies
Menée à l'aide de xénogreffes sur des modèles murins, cette étude française met en évidence des mécanismes suggérant l'intérêt du pegfilgrastim pour renforcer l'efficacité de certains anticorps monoclonaux, notamment le rituximab et le trastuzumab
Therapeutic monoclonal antibodies (mAbs) exert antitumor activity through various mechanisms including apoptotic signalization, complement dependent cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) or phagocytosis (ADCP). G-CSF and GM-CSF have been reported to increase the activity of antibodies in preclinical models and in clinical trials. In order to determine the potential role of pegfilgrastim as an enhancer of anticancer antibodies we performed a comparative study of filgrastim and pegfilgrastim. We found that pegfilgrastim was significantly more potent than filgrastim in murine xenograft models treated with mAbs. This was observed with rituximab in CD20+ models and with trastuzumab in HER2+ models. Stimulation with pegfilgrastim was associated with significant enhancement of leukocyte content in spleen as well as mobilization of activated monocytes/granulocytes from the spleen to the tumor bed. These results suggest that pegfilgrastim could constitute a potent adjuvant for immunotherapy with mAbs possessing ADCC/ADCP properties.
http://mct.aacrjournals.org/content/early/2016/03/17/1535-7163.MCT-15-0759.abstract